Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6 ...

Shares of Vera Therapeutics (VERA) sold off about 20% on Friday following news in competitor Otsuka’s 2024 earnings presentation that the ...

Evercore ISI analyst David Palmer is adding Wendy’s (WEN) to the firm’s “Tactical Outperform List” as the firm sees upside heading into Wendy’s ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” ...

Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...

While Evercore ISI acknowledged these challenges are "addressable," the firm believes it will take time to resolve them. "We may be wrong in our fundamental attribution, but this is our best guess ...

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Closing Bell Overtime' to talk Airbnb and Roku earnings.

Fears that DeepSeek may be moving AI workloads from Nvidia's GPUs to Application-Specific Integrated Circuits combined with possible delays in the Blackwell chip release have caused lags in Nvidia ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (LSE:0VRQ) from In-Line to Outperform. There are 577 funds or institutions reporting ...